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Abstract Although applications are being developed
and have reached the market, nanopharmacy to date is
generally still conceived as an emerging technology.
Its concept is ill-defined. Nanopharmacy can also be
construed as a converging technology, which com-
bines features of multiple technologies, ranging from
nanotechnology to medicine and ICT. It is still
debated whether its features give rise to new ethical
issues or that issues associated with nanopharma are
merely an extension of existing issues in the under-
lying fields. We argue here that, regardless of the
alleged newness of the ethical issues involved,
developments occasioned by technological advances
affect the roles played by stakeholders in the field of
nanopharmacy to such an extent that this calls for a
different approach to responsible innovation in this
field. Specific features associated with nanopharmacy
itself and features introduced to the associated
converging technologies- bring about a shift in the
roles of stakeholders that call for a different approach
to responsibility. We suggest that Value Sensitive
Design is a suitable framework to involve stakeholders
in addressing moral issues responsibly at an early stage
of development of new nanopharmaceuticals.
Keywords Nanopharmaceuticals.Technological
risk.Convergingtechnologies.Ethicalissue.Social
impact.Valuesensitivedesign.ICT.
Nanoinformatics.Personalizedmedicine
Introduction
Nanomedicine has triggered many discussions and
concerns for scientists, philosophers, ethicists and
policy-makers. Nanopharmacy is a branch of nano-
medicine that is already making its way out of the
laboratory to the market. As an instance of converging
technologies, nanopharmacy gives rise to a myriad of
ethical and social issues stemming from different
technologies such as nanotechnology and bioelectronics
and ICTin general. Besides giving rise to pressing ethical
issues, nanopharmaceutical innovations also have far
reaching implications for health care in general [62].
New high tech medicines will emerge that challenge
the way health care currently is practised and that call
for a different approach to dealing with these ethical
issues. The following examples illustrate this
development.
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The miniaturization in health care fuelled by nano-
technology will enable development of nanochips that
are able to make multiple-parameter measurements on
blood-cells and human genomes [62]. These measure-
ments can be carried out by hand-held devices called
‘laboratory on a chip’. This will make it possible to
assess the (future) health status of an individual very
accurately. The digital information gathered can be
further analyzed by database-matching programs and
statistical methods for a further diagnose. The
combination of nanotechnology and ICT thus facili-
tates a new predictive medicine offering a personal-
ized diagnose that can be used to tailor medical
treatment and health care to the needs of the
individual, so-called personalized health care or
medicine (Califf 2004).
Doctor in a Cell
Limits of health care practise are further pushed by
another development that is already in progress,
called ‘Doctor in a Cell’. The vision behind this can
be summarized as ‘a molecular medical team that can
be injected into a patient, coursing through his
bloodstream and treat it’ [11]. It consists of a
biological computer able to process and analyze
biological signals, send out a diagnosis and even treat
the patient [35]. First steps already have been taken to
realize this vision. Although not working on humans,
researchers have created a molecular computer that is
able to diagnose defects in DNA and destroy them
[11].
BioSilicon
Another example illustrates that boundaries between
medical products, devices and therapies are likely to
become blurred is the drug delivery system BioSili-
con. BioSilicon ‘is a nanostructured form of elemental
silicon that is engineered to create a “honeycomb”
structure of pores. This structure allows silicon to
biodegrade while also allowing the retention of
various drugs and vaccines within the honeycomb
matrix.’ [13] BioSilicon thus acts both as a drug and
as a medical devise. As a result nanopharmaceuticals
as BioSilicon, termed ‘borderline products’, no longer
fit the standards currently used to identify and classify
medicine [13]. Consequently concerns are raised
about the suitableness of existing regulatory frame-
works and testing methods of nanopharmaceuticals,
as well as about knowledge gaps, questions of
expertise and definition issues that the blurring of
boundaries will entail.
The BioSilicon example indicates that current
regulation may not be up to the challenges posed
by nanopharmacy. Blurring boundaries will chal-
lenge the competence of regulatory bodies in the
future as nanomedicine will continue to fulfil its
promises. Although legislators, especially in the
EU, do anticipate future medical innovations, for
the time being they regulate nanomedical products
and devices under the existing regulatory structures
[13]. The general stance, most notably in the US,
therefore is anticipatory and not proactive. A concern
is raised that this may hamper development of
nanopharmaceuticals as ‘appropriate and effective
regulatory structures will be critical in the successful
implementation of nanomedicine and the fulfilment of
its promise’ [13].
Willingness to see the far reaching implications of
nanopharmacy as a converging technology crossing
traditional boundaries between disciplines is vital to
the success of nanopharmacy. This is not only true for
legislators, the same holds for other stakeholders
involved in health care in general such as doctors,
patients and developers of nanopharmaceuticals.
As is clear from these examples, the traditional
actors involved in medical practice are not able to
assess and control the technological artefacts. The
burden of responsibility shifts to technological spe-
cialists involved in the design and implementation
[36]. In this paper we argue that Value Sensitive
Design offers a methodological stance that can help to
bridge the gap between responsibility and design for
nanopharmaceuticals.
We start by giving a conceptual analysis of nano-
pharmacy building on its emerging and converging
character. Next, we discuss some fundamental devel-
opments triggered by nanopharmacy and the issues
that stem from those developments. Special attention
is paid to the overarching issue of dealing with these
issues responsibly given the revolutionizing effect of
nanopharmacy on healthcare in general. The paper
concludes with a discussion on how the Value
Sensitive Design (VSD) methodology can be applied
to address the issues responsibly.
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We first discuss the idea of nanopharmacy by drawing
upon a general characterization of nanotechnology.
Nanotechnology is a multidisciplinary field of re-
search concerned with the physical and chemical
properties of chemical substances and materials on the
scale of nano sized particles (from 0.1 nm to 100 nm)
[5, 34]. It also studies the techniques that can be used
to manipulate materials utilizing these special charac-
teristics. The essence of nanotechnology is that new
products with specifically designed target functions
and special characteristics can be manufactured by
means of artificial manipulation on the level of atoms
and molecules. It is widely accepted by now that the
application of nanotechnology will change the design
and manufacturing procedures for pharmaceutical
products [8, 59]. What’s more, it has even been
argued that the novel approach it enables will
revolutionize the future of medicine [7, 26].
Nanotechnology in a short period has already
brought vital changes in many practical areas of
health care from the 1990’s up till now. For example,
in the field of diagnostics nano-chips are used to
develop self tests and home diagnosis for some
diseases [45]. Other applications include the use of
quantum dots for more sensitive detection and nano
needles which allow for surgery on nanoscale
structures inside living cells and tissues without
causing any damage [2]. Finally speculations about
future applications predict even further reaching
possibilities such as the use of multifunctional nano-
robots that can operate as a self-contained entity to
‘diagnoze, treat, and monitor diseases […]’ [8].
Although there still are many technical barriers to
overcome, these futuristic applications do raise
specific ethical concerns that already attract attention
in current ethical discourse.
Apart from nanotechnology, nanopharmacy integra-
tes medicine, pharmacology, biology as well as infor-
mation and communication technology (ICT).
Nanopharmacy therefore must be considered as an
instanceofa techno-scientific complexcalled“converg-
ing technologies” [32]. “Converging Technologies” is
a label nowadays used to point at synergies between
originally separate fields leading to revolutionary
innovations and thereby new impacts. Besides ethical
issues associated with the individual technologies, the
merger of disciplines in a converging technology
issues arise that transcend particular local discourses
[32, 47]. In the discussion of issues and developments
below, issues stemming from individual technologies
as well as the converging technology are implicated.
Although some nanopharmaceuticals have reached
the market, these are still early and basic examples of
applications. More revolutionary applications still lay
ahead of us [26]. In this stadium it is still uncertain
which of the applications and associated issues will
materialize. Also the issues and applications discussed
in this paper are often based on projections. We
nevertheless think it is worthwhile to discuss them.
Even if these specific applications and issues will
never appear, they are likely to provide insights that
do apply to developments that will be realized in
practice [27]. Moreover, the suggested methodology
for dealing with these issues is not bound by specific
applications or issues, but provides a general ap-
proach to deal with human values in innovative
design processes.
Like nanotechnology in general [5], at present,
nanopharmacy lacks a clear, broadly accepted defini-
tion. Analogous to the definition of “nano-medicine”,
“nano-pharmacy” may be defined as “the uses for
nanotechnology in pharmacy”. Although this defini-
tion looks overly simplistic, it is all that is needed at
this stage of the investigation. A too strict definition
might limit the scope of (ethical) investigation to
exclude important issues.
Although the fields to a large extend overlap, are
sometimes used interchangeably, and are often dis-
cussed next to each other—see also our discussion
below- nanopharmacy can be distinguished from
nanomedicine. This can be made clear by looking at
the relation between medicine and pharmacy in
general. Medicines must be understood as ‘therapeu-
tics, administered to patients by clinicians’, while
pharmacy involves the manufacturing and researching
of medicine predominantly by pharmaceutical com-
panies [14]. This means for instance that also the
translation of research into marketable medicine is a
key consideration of nanopharmacy.
We think we can usefully distinguish between four
perspectives to further refine our definition of
nanopharmacy:
1. The materials used in nanopharmacy share specific
propertiesthat setthemapartfrom other technologies
[32], the most common property being its
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physical properties, surface charge and shape are
typically associated with nanopharmacy [5].
2. On a process level certain functions are attributed
to nanopharmacy that have enormous potential in
addressing the failures of traditional drugs [6].
Typically nanoparticles are mentioned as agents
for (targeted) drug delivery, quantitative drugs
release, imaging and diagnosis.
3. Nanopharmacy includes all the practical fields
linking to nanopharmaceutical research and de-
velopment (R&D), nanopharmaceuticals manu-
facturing, nanopharmaceuticals application and
nanopharmaceuticals management.
4. Nanopharmacy is an instance of converging
technologies, integrating disciplines including
emerging technological fields such as nanotech-
nology, biotechnology and informatics.
Main Developments and Issues of Nanopharmacy
Nanopharmacy includes the research and develop-
ment concerning nanopharmaceuticals, the manufac-
turing of nanopharmaceuticals, the application of
nanopharmaceuticals as well as the management of
nanopharmaceuticals. Using this broad view allows us
to analyze the potential impact of nanopharmacy on
health care system from the different perspectives.
In this section we discuss how technological
advances in nanopharmacy as a converging technol-
ogy fuel changes in the medical practice at large. By
outlining these developments and the ethical and
social issues implicated by these developments, we
discuss how actors involved in nanopharmacy and
medical practice are affected.
First the implications of nanotechnology on health
practice as such are discussed together with its ethical
implications, seconds social implications of nano-
pharmacy are discussed and finally, the implications
that can be attributed more specifically to ICT as an
enabler for nanopharmacy are analyzed.
Nano and Medicine
As its main constitutive technology, that sets it apart
from pharmacy in general, issues associated with
nanotechnology are applicable to nanopharmacy as
well. Nanotechnology can be described as “[t]he
design, characterization, production, and application
of structures, devices, and systems by controlled
manipulation of size and shape at the nanometer scale
(atomic, molecular, and macromolecular scale) that
produces structures, devices, and systems with at least
one novel/superior characteristic or property” [6].
Working at nanoscale, ordinary materials can exhibit
extraordinary properties that give rise to specific risk
to cause harm [34]. Although the newness of nano-
ethical issues is debated, scholars agree on a wide
range of issues associated to nano [3, 9, 27, 49, 58].
Below, some of the more pressing developments and
issues with respect to healthcare are described.
Revolutionizing Healthcare
Nanotechnology holds a lot of promises to medicine,
although most are yet to be fulfilled. That being said,
there already are many applications on the market
showing us a glimpse of what lies ahead (see section
Conception of Nanopharmacy). Nanomedicine is
often portrayed as the future of medicine with the
potential to radically change the way is practiced
today [7, 8]. Improvement in the way medicine is
delivered into the body, more accurate and faster
diagnose and treatment of illnesses or often men-
tioned [8, 59]. Nanopharmaceuticals allegedly have
enormous potential in addressing the failures of
traditional drugs such as lack of target specificity
and poor water solubility [6]. The effectiveness of
drugs will increase by the ability to avoid collateral
effects, for instance in chemotherapy, and use lower
dosages [48]. Furthermore, nanomedicine will enable
monitoring progress of medication on a person real
time allowing doctors to check effectiveness of a
treatment immediately [48]. Besides improving exist-
ing treatment options also new ones are created. For
example, nano-particles able to pass the blood–brain
barrier, a membrane which traditional drugs cannot
pass, opens up ‘new possibilities for treatment of
psychiatric disorders, brain injuries, or even the
administration of neural anesthetic’ [2].
It is argued that all these and other changes will
amount to ‘a radical change in the basic infrastructure
of the health care system, including the health care
workforce’ [8]. Ultimately this change can be classi-
fied as a ‘shift from the hospital to the laboratory’ [8]
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a broader perspective.
Safety & Human Health Risks
One of the most significant risks associated with
nanotechnology is the toxicity of nano-particles [8].
Although humans already are exposed by natural
nanoparticules such as viruses and by products of
combustion, the impact of manufactured nanomate-
rials may pose a health hazard. Reactivity of nano-
particles is depending on its size, surface to mass
ratio, and bioreactivity [8]. Increased toxicity is
indicated with carbon nanotubes and the application
of certain metals as nanomaterial [7]. Even when
substances are used that in normal conditions are not
be toxic, on a nano-level alteration of its properties
can imply that they become toxic. What’s more,
disintegration of nano-particles into smaller toxic
particles may only take place after they have entered
the human body [26]. So long term effects of particles
may differ from those on short term. Although actual
effects of nanotechnology on humans in most cases
are still uncertain, it is generally accepted that use
nano particles may cause health problems [2].
In relation to the use of nanomaterials for medical
purposes, many concerns have been raised about
conceivable toxicity of nanomedicine [2]. For in-
stance, during treatments nanoparticles can uninten-
tionally cause damage to healthy tissue [44]. Other
concerns raised are the penetration of highly charged
nanoparticles of the skin potentially damaging it and
the possibility that nanoshells used to deliver drugs
will accumulate in the body and cause damage [5].
Overall it is concluded that research should be
done to provide more insight into the effects of
nanoparticles on humans [5]. Only then a responsible
trade off can be made between the health risks of
applying nanomedicine and its benefits to patients as
is the best practice with conventional medicine [26].
Risks Related to Diagnoses
The increase in diagnostic abilities provided by nano-
technology can cause psychosocial harms such an
increased anxiety and fear about illnesses [26]. The
ability to detect a single cancerous cell, for instance,
‘could have profound effects upon how individuals
think about the status of their health and bodies’ [5].
Increased diagnostic abilities cause a heightened
awareness of one’s health status which could increase
fear and anxiety about illness.
Besides more accurate diagnostics, nanotechnolo-
gy also enables faster diagnoses and treatment. A
concern has been raised that this might lead to an
increase of the possibility of misdiagnoses and
inappropriate treatments [26].
Finally the ability for self diagnoses that is
associated with nanomedicine might result in
avoidance of doctors due ‘to the fear and high
costs of medical assistance and treatment [26].
Although it is argued that nanomedicine will be
expensive due to high development costs involved
[8, 59], it is not unlikely that, parallel to other high
tech products such as laptops, that once they are
mass-produced the price will drop considerably. In
fact, pharmaceutical companies already mention cost
reduction on the long run as one of their main
arguments to invest in nanotechnology [8, 19].
Re-conceptualization Issues
The introduction of nanomedicine pushes the
boundaries of many of the key concepts associated
with healthcare.
First, the concern is raised that as boundaries
between nanotechnology, ICT, biotechnology and
cognitive sciences disappear our concept of what it
means to be human will change radically [16, 53].
The introduction of nano-chip implants, for instance,
may enable unprecedented interactions between man
and machine on a nanolevel thereby introducing a
kind of hybrid humans [26]. These developments
affect our view on what it means to be human [5], our
human identity, and raises questions about the
preservation of human dignity [26, 48].
Second, this will also entail questions on how
human disease should be defined and how treatment
of a disease is to be approached [5]. New diagnostic
possibilities offered by nanotechnology increase our
understanding of an illness and thereby raise the
question of what a disease actually implies [26].
Better diagnostics also means we need to reassess the
distinction between what it means to be healthy and to
be ill [5]. Third, drawing a clear cut boundary
between improving human capabilities and preserving
existing ones may increasingly become blurred [8].
This will raise the ethical concerns about what it
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ity’ gets a new meaning, whether society can require
certain persons to be enhanced, e.g. soldiers, or
surgeons, and whether focussing attention and funds
on enhancement will leave certain diseases and
diseased persons untreated [47]. This has drastic
consequences for the conceptualization of pharma-
ceuticals, drugs and medicine since they are typically
construed in relation to alleviating and curing disease
and restoring the organism to its proper and normal
function. This may change as a result of enhancing
designer nano-medicine.
It is implicated that these conceptual developments
will ‘have a significant impact on health care
professionals and patients.’ [5] Not only their under-
standing of what concepts such as health and illness
alters, also their expectations of what to expect from
healthcare and their role in receiving and giving
medical care may shift considerably.
Informed Consent
Regarding special characteristics of the risks for
nanopharmaceuticals, another related problem must
be considered, namely informed consent. Although
often brought up in relation to the clinical trials of
nanopharmaceuticals [48] it could also be framed as
a general concern to applying of nanomaterials for
medical purposes in general [9]. The notion ‘in-
formed’ encompasses disclosure and comprehension
of the technology being used, including any known
risks and benefits [30]. ‘Consent’ includes voluntar-
iness, competence and agreement of the person
affected [50]. This implies that affected persons
voluntarily agree to subject themselves to the tech-
nology [30]. In the light of the considerations
discussed above, informed consent is problematic.
As long as nanopharmaceuticals are associated with
risks, but also with significant uncertainty and
ignorance (“unknown unknowns”), it may prove an
impossible task to inform affected persons adequately.
Harms to the Environment
The potential impact of nanoparticles on the environment
has aroused concerns. For instance, quantum dots, and
colloids delivering drugs may constitute non-
biodegradable pollutants. They could provide an avenue
for rapid and long-range transport of waste in
underground water [4]. Another concern raised is that
the production of nanopharmaceuticals will affect the
environment in which they are manufactured causing
harm to workers involved in different stages of the
production process [45].
Disposal of nanopharmaceuticals may also be
problematic. Even when initially harmless particles
enter the environment a risk occurs. This is because
after a while their chemical bond can be broke off and
radicals can be recombined so that new materials are
generated. Indeed, the practitioners do not know
whether or not the new materials thus generated are
toxic [31]. What’s more the wastes for nanopharma-
ceuticals can be trans-located and impact other plants
and animals via the food chain. For instance, iron
nanoparticles can transform within ground water over
a distance of 20 m and remain reactive for 4–8 weeks
[18]. It is expected that current and future dissemina-
tion of nanoparticles will make unintentional expo-
sure to them unavoidable [32].
Nanopharmacy and Society
Besides issues that affect individuals or groups of
individuals, nanopharmcacy has also wider social
impacts. Special institutional reform accommodating the
problemsdiscussedaboveneedstoberealized.Plantsand
R&D facilities need to be designed in order to adequately
deal with security and dual use issues (see [39]). Public
discussions and awareness campaigns need to be
started, and legislation needs to be prepared.
Push by Market and Government
An important driver behind the amount of attention and
investment nanotechnology currently receives, not the
least in the field of medicine is the business opportunity it
is seen to offer by both private and public organizations.
The pharmaceutical industry views nanotechnology as a
means to ‘develop methods that simplify, speed up, and
reduce the costs of drug development and testing, as well
as increasing drug safety and efficacy’ [8]. Of signifi-
cance to the public is not only the promise it hold to
create jobs and prosperity, but also to make medicine
more effective and widely available, thereby boosting
economy and national health and life expectancy [15].
Beyond mere therapeutic applications, nanomedicine
will enable forms of human enhancement that expand
human cognitive and physical capabilities thereby
274 Nanoethics (2011) 5:269–283potentially enriching human life and wellbeing [34].
These positive prospects of nanomedicine can be traced
back in investments in R&D by both public and private
organizations. In the US hundreds of millions of public
money is invested by the National Nanotechnology
Initiative (NNI) [8], as does its European counterpart
the EU Nano, Materials and Production (NMP)-
program that invests hundreds of millions Euros in
nano related research [25]. In the private sector it has
been reported that venture capitalists and corporations
are spending several billion US dollars on nanotech-
nology R&D globally [5]. These numbers further
underline the urgency that is felt to develop and
market nanopharmaceutical applications.
Social Fairness and Justice
From a cost-benefit perspective, research and devel-
opment (R&D) concerning nanopharmaceuticals has a
long-term cycle and consequently involves a high
investment risk [61]. Acceptance of new drug
formulations for instance is expensive and slow,
taking up to 15 years to obtain accreditation of new
drug formulas with no guarantee of success [4]. These
facts indicate that nanopharmaceuticals will be rela-
tively expensive at last in the short term. The costs
may therefore increase the divide between rich and
poor within and across countries [8] and contribute to
unequal access to health care.
Public Backlash
The novel effectiveness of nanopharmaceuticals makes
the public highly aware of the risks of nanopharmacy. In
some case, uses of nanotechnology may be promoted so
extensively that it becomes a hype detached from reality
[5], which may occur for instance if pharmaceutical
companies conceal side-effects and risks of nanodrugs
in order to increase their economic benefits. A lack of
understanding of the nature and impact of nano-
pharmaceuticals and lower level of public awareness
of nanotechnology leads to irrational choices of
patients and consumers. A concern is that a hype will
conceal ethical and social implications of nanotech-
nology. Hyping nanotechnology has also the risk of
backfiring. A great challenge facing Nanopharmacy
then is avoiding a backlash from the public akin to
that seen with genetically-modified food in Europe
[40] that can slow or even halt the progress of
research and development [46]. In a similar vein, a
possible withdrawal of investors and market support
due to a negative public opinion on nanopharmaceut-
icals also may hamper progress [8].
Technological Fix
The current optimism towards the possibilities of
nanotechnology in general and nanomedicine in
particular entails a belief that it can “fix” anything
[8]. Emphasis on human ingenuity and the ability to
control nature not only seem overly optimistic, but
may also lead to irresponsible behaviour. The stronger
the belief that nanomedicine is able to fix you, ‘the
less incentive there is to engage in responsible health
practices, such as a healthy diet, exercise, and routine
primary and preventive care.’ [8]
Nontranslatability and Time to Market
Nontranslatability of researcher’s ideas to large-scale
manufacturing is a major issue in nanopharmacy [14].
If ideas cannot be produced at large scale, investments
in R&D cannot be recovered. Requirements of
translatability include repeatability of a design,
stability and consistency of a new drug. These
requirements set limits to which researched medicines
can be actually produced and marketed at large scale.
Apart from practical translatability a drug can be
prevented from entering the market due to a lack of
reimbursement [14]. When price per therapeutic dose
or treatment become too high, cost becomes an issue.
In those cases it is not worthwhile for pharmaceutical
companies to invest in new drugs.
A further consideration in this respect is the time to
market of a nanopharmaceutical. Even when an idea
is translatable, the time to market of a new drug may
be too lengthy. Manufacturers who enter the market
first or second are likely to be reimbursed for their
investments, and will likely have a substantial market
share [14]. Those who enter the market later must
have an extra edge over their competitors, for instance
less side effects or better therapeutic outcome [14].
Changing Regulation
Regulations for the approval of a drug are constantly
changing [14]. Pharmaceutical companies therefore
run the risk of developing a drug that does not comply
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R&D the drug was compliant. Uncertainty about
regulation is partially caused by a lack of knowledge
of nanomaterials. Companies run a great risk when
drugs are developed whose impacts on humans and
environment are hard to quantify. On the other hand,
in some cases regulators may be more flexible ‘if
there is a prospect of a significant improvement in the
prognoses of a serious disease’ [14]. Considering the
huge investments needed to develop and market a
new drug, uncertainty about future regulation entails a
huge risk to pharmaceutical companies.
Nontranslatability and other commercial considera-
tions indicate that societal or patient’s value and
commercial feasibility success sometimes can be at
odds. Pharmaceutical companies have to evaluate at
each stage starting at the research stage of a nano-
pharmaceutical whether continuation is commercially
feasible. Outlook on reimbursement therefore should be
at the heart of any evaluation of nanopharmaceuticals.
Nano, Medicine and ICT: Developments & Issues
A si n f o r m a t i z a t i o na n dm i n i a t u r i z a t i o ng oh a n di nh a n d ,
the relationship between nanotechnology and ICT must
be seen as twofold [53]. On the one hand nanotech-
nology is a crucial enabler to the development of
computers on a nano scale that will be much more
powerful than any computer we have at this point in
time [61]. On the other hand are the possibilities of
nanotechnological applications such as in nanophar-
macy greatly enhanced by the possibilities offered by
computers [1]. Computational techniques can be used
as intrinsic part of a nanopharmaceutical or as an
external counterpart used to analyse and process data
gathered by the nanopharmaceutical. Nanoinfor-
matics, which operates at the intersection between
informatics, nanotechnology and medicine, refers to
‘the use of informatics techniques for analyzing and
processing information about the structure and
physico-chemical characteristics of nanoparticles,
their interactions with their biological environments,
and their applications’[1]. One of the goals of nano-
informatics is to structure information in nanomedi-
cine to make it more widely available. One way to
realize this, for example, is by integrating data from
nanomedical-sources in Electronic Health Records
(EHR) [1]. Another is to apply knowledge extraction
techniques such as data mining and text mining on the
data collected. It is anticipated that in the (near) future
ICT techniques such as data mining and combining
data from different sources will become part of
nanopharmaceutical services offered to medical pro-
fessionals but also (directly) to patients or customers
[1]. Finally the integration of nanopharmacy with grid
and cloud computing is an important development as
it introduces new ethical issues that are related to the
use of grids and clouds, and also exacerbates issues
already associated with nanomedicine [1].
Personalized Medicine
One of the most striking developments in this respect
is the contribution of ICT enabled nanotechnology to
personalized medicine [1]. It is anticipated that in the
next 10 to 15 years the diagnostic and therapeutic
advancements made possible by nanomaterials will
enable custom treatments to specific individual needs
[7]. A fundamental shift in the model of medicine will
take place. Instead of reactive model of medicine
geared towards diagnosing and treating acute diseases
once they develop, increasingly a proactive model of
medicine will become dominant that anticipates
illnesses by deploying predictive and preventive
measures [8]. For example, it is suggested that
nanomedicine will make it possible to create a
regenerative medicine that can repair human tissues
to treat diseases and injuries [44].
Currently personalized medicine still is in its early
stagesofdevelopmentandnotwelldefinedyet.Also,itis
unclear how much investment is needed and what the
costs of actual implementation will be [8]. Despite
uncertainty surrounding it, technology advances and
economical prospects indicate that personalized med-
icine in one form or the other will be realized some
day. What is clear though is that developments such
as personalized medicine have a profound potential to
reshape healthcare as we know it today.
Pharmacogenetics: Patient and Disease
Stratification
1
An important enabler and forerunner of truly personal-
ized medicine is pharmacogenetics.Potential possibilities
1 We thank an anonymous reviewer of the journal for the
valuable suggestion to draw a comparison of nanopharmacy
with pharmacogenetics.
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carry over to personalized medicine and nanopharmacy.
Pharmacogenetics enables the replacement of general
applicable medicine bymedicationtailoredtothe specific
genetic traits of a patient [24]. Possible improvements
that this technology entails include increasing medical
effectiveness, decreasing adverse drug reactions and
lowering health costs [43]. Pharmacogenetics may
also affect the value of justice in two ways [52]. On
the one hand it facilitates the identification and use of
difference between individuals and leads to more
justice as it enables a way to overcome moral
differences amongst patients and thereby offering
them the same care. Especially variations in safety
and efficacy of medications vary between individuals.
Connecting genotype to such variations make it
possible to make a trade-off between these two values
per genotype instead of an entire population. On the
other hand pharmacogenetics may lead to injustice in
two following ways: ‘through the inappropriate use of
the differences identified by pharmacogenetics or,
through the inappropriate failure to use such differ-
ences’[52]. Stratification of patients for instance may
exclude certain small genetic subgroups -so called
‘orphans’- from getting proper therapy as their group
is too small for commercial exploitation [24].
Furthermore, pharmacogenetics may only be accessi-
ble for the rich thus excluding the poor. For one, only
health care systems ‘with significant resources and good
infrastructure will be able to use the technology’[24].
Because pharmacogenetics may produce significantly
better results than the traditional drugs that are
accessible to (some of) the poor, inequality in health-
care does entail inequality more broadly as well [24].
Besides the benefits, the risks created by pharmaco-
genetics may be unequally distributed between genet-
ic sub-groups as well [52]. As drugs are developed
and tested specifically for a certain genetic sub-group,
other groups excluded from trials run a risk for
instance ‘in the event of inadvertent or inappropriate
off-label prescribing’[52]. Lastly, genetic stratification
may lead to discrimination and stigmatization of
certain groups that share specific traits such as a poor
response to certain medications [52].
Costs of Healthcare
Depending on its innovativeness, generally costs of
introducing a new pharmaceutical product will be several
hundred million US dollars [5]. Although prices paid
by consumers or patients over time will steadily drop,
initially nanopharmaceuticals will be costly since
companies have to recover substantial investments
[8]. Personalized medicine for example may prove to
be a financial burden as it stimulates the use of costly
preventive approaches [1]. On the positive, it is also
claimed that nanotechnology will make certain pro-
cesses faster and cheaper [8]. Also use of information
t e c h n o l o g ym a yh e l pi np lanning and allocating
resources more efficiently, for instance by identifying
patients that will benefit from a specific nanomedi-
cine, so they can be targeted more cost effectively [1].
Moreover, it is also argued that nanomedicine on the
longer run will reduce societal and economic costs
associated with healthcare and improve clinical out-
comes for the patient at the same time [5]. Like with
other mass produced high tech products, scaling up
the production of nanopharmaceuticals will lower the
prices rapidly.
Changing Roles in Medicine
Nanotechnology in general is attributed disruptive
qualities. Other products and processes are put
under pressure to realign themselves around it [8].
Consequently it potentially transforms such things as
social relations, labour, economies and institutions
[8]. This also holds for nanomedicine. It is argued that
it will revolutionize the healthcare system and the
practice of medicine in an unprecedented way [26],
dwarfing ‘all other trends in the history of medical
technology’ [38].
One trend is the change in the roles of individuals in
the health care system. Technology will empower
patients and increase control over their life [1]. Person-
alized medicine for instance enables patients to
diagnose and treat themselves without consulting
medical practitioners. An anticipated effect is that
people will become and should become to a greater
extent responsible for their decision making (Califf
2004). Based on the detailed information offered by
medical devices about their health status they should
be able to make rational choices concerning their
healthcare. This raises the question whether more
autonomy leads to better healthcare: i.e. will a patient
be able to make good decisions. The fact that a body
and its disease are not a singular matter makes
diagnosing and treatment a complex and messy thing,
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What’s more, even if technology enables us to do so,
this doesn’t mean that patients will. Mol argues that
while autonomy is an important moral value, it is no
goal in itself. Good care may involve restricting
patient’s autonomy in favour of trained professionals
such as doctors [42]. Furthermore, what amount to
good care or the better treatment is not always
straightforward. Treatment of diabetes patients for
instance may involve a trade-off between a longer
life, or a life lived more intensely [42]. It may prove
to be a daunting task for a patient, or even a doctor, to
interpret the information offered by nanopharmaceut-
ical devises and apply them to their specific case
while taking health, moral and social implications into
consideration.
An increase in the contribution of technology in
healthcare processes is likely to be accompanied by a
decrease in the influence of medical specialists. As
systems become more complex, it is harder for an
individual specialist to combine the competences needed
especially specific technological expertise [32]. In a
converging field such as nanomedicine that covers a
range of specialized technologies, this will be even
more so, especially for traditional medical professio-
nals that lack any training in these disciples. What’s
more, personalized medicine adds to the autonomy of
patients at the expense of medical professional’s
influence [48]. The influence of doctors on patients
is further diminished by reduction of personal
interaction cause by technology [48]. In all, the role
of medical professionals may alter considerably due
to introduction of advanced nanopharmaceutical
products. Also, increasing importance of ICT and
nanoinformatics in medical practise will entail a more
substantial role for computer scientists not just in
research and development of new nanomedicine, but
in (supporting) implementation as well, for instance in
knowledge management or actual lab work [1].
Data Overflow
Fuelled by the success of the internet, an enormous
amount of (bio) medical information has become
available for practitioners, researchers, patients and
the public in general [1]. The enhanced diagnostic
capabilities of nanopharmaceuticals promise to push
these boundaries even further by enabling more
accurate and detailed monitoring. The concern is
raised that this explosion of the amount of medical
data may ‘eventually overwhelm the ability of health
information systems to evaluate it—making effective
treatment impossible’ [5]. As the amount of data
generated may prove to be too vast for individuals to
reach a timely diagnose or diagnose at all as it
becomes harder to separate relevant data from the
irrelevant, support by ICT, such as data mining tools,
will become vital. Again, this development indicates
an increase in dependency of medical practitioners on
technology. Below we will argue that this dependency
entails a shift of control and responsibility from
traditional medical professionals and patients to
computer scientists and other technical experts.
Privacy
The diagnostic and surveillance [56] possibilities of
nanotechnology combined with ICTs raise concerns
about privacy. For instance, monitoring by a
implanted nanochip brings up the question of who
has access to the data collected and for what purposes
this data is been used [26, 37]. The usage of
biometrics and ICT implants “anytime and anywhere
inherits that too many people, state authorities, or
even companies will know too much about us. There
will be too many opportunities to use personal related
information against us” [60]. For instance, intercep-
tion of sensitive data by health insurance companies
or employers could affect ‘insurance coverage, em-
ployment, or other social conditions where privacy
and confidentiality of patients is paramount’ [1]. In
general privacy is the number one ethical concern in
ICT enabled contexts [29]. When medical data is
involved this issue becomes even more pressing as
people are especially sensitive about their medical
data. The combination of nanopharmaceutical appli-
cations and grid or cloud computing, both suspect to
give rise to privacy concerns, therefore needs extra
careful evaluation with respect to privacy issues.
Other Concerns
Besides privacy concerns, the close collaboration
between nanotechnology and other ICTs will intro-
duce or exacerbate a myriad of ethical issues that are
associated to ICT in general. The value of autonomy
will be at stake as control over medical data shift from
local records to the cloud. This development will also
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service providers who handle the data [54]. Another
issue is related to Intellectual Property (IP), namely
who will own the medical data? [33]. The conver-
gence of medical practice with nanotechnology and
ICTs like cloud computing, AI and robotics thus
intensifies the need to address these ICT related issues
as the fields become more intertwined.
Shift of Responsibility to Address Issues
Being at the intersection of disciplines, nanophar-
macy inherits ethical concerns that its underlying
enabling technologies entail. Convergence exacer-
bates existing problems and in some cases intro-
duces new ones. As technology moves forward, and
millions of dollars are invested and expectations
rise, issues will have to be addressed and resolved.
At the same time, developments in nanopharmacy
radically change the health care system to such an
extent that addressing these issues becomes prob-
lematic. Personalized medicine, for instance, enhan-
ces the autonomy of the patient and user by giving
them more control, but at the same time shifts
responsibility and liability to the service providers
and product developers because medical professio-
nals slowly move out of the picture. What’sm o r e ,
convergence of high tech disciplines makes it
increasingly difficult for specialists in one field to
assess the work of others also involved in the
process. In all, medical professionals but also
patients will be less able to assess the workings
and output of nanopharmaceuticals and must rely
on its workings as they are designed into them. The
developments outlined indicate a shift towards the
designer or engineer as a responsible agent in the
healthcare at the expense of traditional medical
practitioner, calls for a new reveille: a design turn
in ethics [55].
Instead of conducting an ethical analysis and
evaluation after a drug has been designed or taken
in production, it should be incorporated into the
design phase of a new drug. In this way designers
and producers of nanopharmaceuticals can take
their responsibility to address ethical issues impli-
cated. This will also lower the risks of investment
as possible hiccups in the introduction of a new
drug due to moral concerns are addressed
beforehand.
Design Turn in Ethics: Designer Nanodrugs
So far we have been analysing nanopharmacy with
respect to main developments and issues that are
implicated in these developments. We showed that
multiple ethical and social issues arise that need
attention. Also it became clear that the traditional way
of addressing these issues is becoming problematic as
the roles and stakes change due to the developments
instigated by technological advances. In this section
we suggest a methodology that does justice to this
shift of responsibility in addressing ethical issues to
an earlier stage in the life cycle of nanopharmaceut-
ical, namely Value Sensitive Design (VSD). Although
it originates from the field of Human Computer
Interaction (HCI) over the years VSD has spread to
other a range of other fields, often specialized
branches of ICT such as Affective Computing [51]
and Augmented Reality [22]. It supports hands-on
development of high tech products while taking social
and ethical issues into account. This methodology
therefore is particularly fit to support design processes
that couple dynamic and rapid development to
uncertainty and urgent ethical concerns as the field
of nanopharmacy does.
VSD starts from the premise that technology
applications are non-neutral or value laden in the
sense that they have a political or morally relevant
impact on individuals and society [57]. Acting in
accordance with moral values such as freedom,
equality, trust, autonomy or privacy justice is facili-
tated or constrained by technology [21]. Where other
design frameworks focus on functional requirements
such as usability, efficiency or speed, VSD primarily
and specifically focuses on values and requirements
of moral import. More specifically it aims at
reconciling different and opposing values in engineer-
ing design or innovations [57]. Typically ethical and
social issues associated with a technology application
are related to certain social or moral values that the
technology embodies. By analysing the value and
operationalize it into the design, ethical issues can be
addressed in the design phase.
VSD does not aspire to offer a full-fledged design
methodology. Rather it must be viewed as a tool that
augments design processes that already exist [12].
Because VSD follows a pattern that is generally used
by often used engineering approaches, it can be easily
incorporated into already established design processes
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pharmacy would therefore require a thorough under-
standingof methodologies usedfor nanopharmaceutical
design.Byevaluatingspecifictraitsandneedsofcurrent
design practice, typical stages of VSD such as concep-
tual and empirical investigations can be applied to meet
those requirements. Conceptual investigation would
typically involve researching values associated with
ethical issues discerned.
A natural starting point would be the four well-
established ethical principles of healthcare: autonomy,
beneficence, non-malfeasance and justice [1]. These
values indicate both positive value contribution that
drugs can deliver to patients, as well as many
concerns outlined in section Main Developments and
Issues of Nanopharmacy for instance about safety,
health risks, environmental issues and a variety of
social issues.
An example in nanopharmacy which forms a clear
exemplification of the design for values perspective is
development of a nanoparticle cancer therapeutic.
Throughout this process tradeoffs must be made
between safety and efficacy. Safety would entail not
causing harm, not leaving residues or not causing
detectable biological changes in the patient at any
level [14]. Efficacy indicates to what extent the drug
succeeds in eliminating cancer cells. One of the
parameters affecting efficacy is the amount of toxicity
of the particle as the toxic nanomaterial is needed to
kill cancer cells [20]. This depends on the choice of
drug and the therapeutic dose used. On the other hand
toxicity also is potentially harmful to a patient’s
healthy tissue as well as to the environment when
released from the patient’s body. In balancing the
implicated values in these tradeoffs, moral justifica-
tion of valuations is required. The VSD offers
methods to conceptualize and operationalize the
values implicated by consulting ethical literature,
engaging stakeholders and assessing technological
possibilities.
As ICT is a major enabler of the new nano-
pharmaceutical drugs also values implicated by ICT
need to be considered. Foremost privacy and data
security issues should be addressed as the nano-
pharmaceutical is likely to produce personal medical
data that needs to be analysed and interpreted by
software probably on a different location than the
patient. This may also involve storing data in a grid or
in the cloud as complex data mining techniques or
large scale data comparing is required. Using ICT
thus on the one hand contributes to the human value
of beneficence but on the other hand may also have a
diminishing effect on the autonomy or privacy of a
patient. Actual investigation would require drawing
on available relevant ethical analyses. Literature by
multiple authors [12, 23] offers good examples on
how to commence such investigations.
VSD can also assist researchers and developers in a
pragmatic way to comply with the code of conduct for
responsibleresearchinNanoscienceandnanotechnology
adopted and proposed to the Member States of the EU by
t h eE u r o p e a nC o m m i s s i o ni n2 0 0 8[ 17]. Amongst other
principles it calls for inclusiveness and openness to all
stakeholders, for accountability of researchers and
researchers organisations and ‘for social, environmen-
tal, and human health impacts that their Nano science
and nanotechnology research may impose on present
and future generations.’[32] Stakeholder involvement
is a key feature of VSD. In the conceptual inves-
tigations stage for example it is considered how the
technology could both socially benefit and negatively
impact stakeholders. Both direct and indirect stake-
holders should be considered by the designers.
Stakeholders who interact directly with a technology
are defined direct stakeholders, while those who are
peripherally connected to the technology are indirect
stakeholders [12]. In case of nanopharmacy patients
receiving the medicine and medical professionals
involved would be the direct stakeholders while
bystanders, the public in general, pharmaceutical
companies and companies providing additional serv-
ices such as cloud providers would count as indirect
stakeholders. By connecting the values discerned to
specific stakeholders a more specific picture is
painted of the impact of the nanopharmaceutical. In
this evaluation also economical cost and benefits as
well as and social costs and benefits such as public
health costs can be taken into account.
By aligning current testing practice with empirical
research methods proposed by VSD existing trajecto-
ries of testing nanopharmaceutical can be improved.
Testing a pharmaceutical is bound by strict legal
standards such as the regulatory framework by the
Federal Drugs Agency (FDA) in the US [6]. Concerns
have been raised about gaps that exist in what
currently is legally required in medical testing [28].
Integrating VSD in testing practise could contribute to
covering these gaps. Nanopharmacy as a converging
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issues and implicated values need to be reassessed as
technological advancements and convergence exacer-
bate current issues [5, 16, 32]. Integrating testing
practises could lead to a broader and more thorough
testing of nanopharmaceuticals. For one, values
implicated by nanopharmacy as a converging tech-
nology thus including values stemming from enabling
technologies would be evaluated. Secondly, more
justice would be done to the specific characteristics
of nanotechnology itself, for instance by introducing
post-marketing surveillance (Phase IV) studies [26].
Actual implementation of VSD requires detailed
insights and information of nanopharmacy and med-
ical practice in general. This means researchers and
other specialists in the field of nanopharmacy need to
be involved in the process of refining VSD to specific
requirements at hand, integrating it in existing
methodologies and finally actually implementing
VSD. The theoretical groundwork and practical
experiences on VSD that have been build up over
the last decade provide a rich source to draw upon in
further exploration of a value sensitive approach in
nanopharmaceutical design.
Conclusions
The introduction of nanopharmaceuticals poses new
challenges for the medical health system. Technolog-
ical innovations fuelled by nanotechnology not only
give rise to many pressing ethical and social issues,
they also affect the way issues can be addressed. In
this paper we explored how Value Sensitive Design
offers a way to bridge the gap between ethics and
design needed to address ethical issues before nano-
pharmaceuticals reach the market.
Using a broad conception of nanopharmacy, i.e.
as ‘the uses of nanotechnology in pharmacy’,
allows us to assess the impact of nanopharmacy
on health care in general, and prevents ethical
issues from being excluded from the analysis. By
framing nanopharmacy as an emerging technology
and an instance of converging technologies the
inherent uncertainty and complexity of nanophar-
macy is taken as a starting point of further
investigation. Nanotechnology and ICT as enabling
technologies of nanopharmacy introduce ethical
a n ds o c i a li s s u e ss u c ha sh e a l t ha n ds a f e t yr i s k s ,
environmental risks, conceptual concerns and pos-
sible infringement of privacy and autonomy.
Furthermore, convergence of these and other
technologies in nanopharmacy is likely to exacer-
bate these issues and bring new issues to the table.
Besides these concerns, ICT and nanotechnology
also instigate developments that fundamentally
change how healthcare is practised today. The rise
of personalized medicine and the further enmesh-
ing of pharmacy with emerging ICTs such as grid
and cloud computing affect the roles of both
patients and medical professionals such that it
becomes more difficult for them to deal with
ethical issues in medical practise responsibly.
Technology makes pharmaceutical more specialized
and complex and therefore less assessable and control-
lable by non experts. Next, innovations fuelled by
nanotechnology such as personalized medicine, de-
crease the interaction between patient and medical
professional, shifting responsibility of medical practise
toproducerordeveloper ofnanopharmaceuticals.These
developments in combination with challenges posed by
social and ethical issues call for an approach that
supports dealing with these issues during the design of
nanopharmaceuticals so before they reach the market or
used in medical practise.
The Value Sensitive Design (VSD) approach offers
a practical framework geared towards the addressing
of ethical and social issues during design of techno-
logical systems. It supports ethical analysis of values,
operationalization of values into design, and evalua-
tion of how values are supported and implicated in
technological applications. Although VSD is not yet
tuned to the specific requirements of nanopharmacy a
first exploration provides us with some preliminary
keystones. First it shows how issues can be repre-
sented by values, how stakeholders related to these
values can be involved in the investigation and gives
some clues to further conceptual research in the
future. Second, it indicates possibilities to integrate
VSD into existing medication R&D practises. VSD
integration needs to be established with existing
testing and development methodologies used in
current nanopharmaceutical R&D. The analyses and
approach outlined here are all but conclusive; much
work still needs to be done. From an ethical
perspective, further conceptual investigating of issues
and values implicated by nanopharmacy is required,
but more importantly, on the empirical and technical
Nanoethics (2011) 5:269–283 281side, further explorations must be implemented on
how VSD can be integrating into existing nano-
pharmaceutical R&D practise.
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